These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
366 related articles for article (PubMed ID: 22290264)
1. Studying a complex tumor: potential and pitfalls. Zheng S; Chheda MG; Verhaak RG Cancer J; 2012; 18(1):107-14. PubMed ID: 22290264 [TBL] [Abstract][Full Text] [Related]
2. Genomics and proteomics to determine novel molecular subtypes and predict the response to immunotherapy and the effect of bevacizumab in glioblastoma. Luo D; Luo A; Hu S; Ye G; Li D; Zhao H; Peng B Sci Rep; 2024 Jul; 14(1):17630. PubMed ID: 39085480 [TBL] [Abstract][Full Text] [Related]
4. MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics. Shea A; Harish V; Afzal Z; Chijioke J; Kedir H; Dusmatova S; Roy A; Ramalinga M; Harris B; Blancato J; Verma M; Kumar D Cancer Med; 2016 Aug; 5(8):1917-46. PubMed ID: 27282910 [TBL] [Abstract][Full Text] [Related]
5. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Kim H; Zheng S; Amini SS; Virk SM; Mikkelsen T; Brat DJ; Grimsby J; Sougnez C; Muller F; Hu J; Sloan AE; Cohen ML; Van Meir EG; Scarpace L; Laird PW; Weinstein JN; Lander ES; Gabriel S; Getz G; Meyerson M; Chin L; Barnholtz-Sloan JS; Verhaak RG Genome Res; 2015 Mar; 25(3):316-27. PubMed ID: 25650244 [TBL] [Abstract][Full Text] [Related]
6. Viral vector: potential therapeutic for glioblastoma multiforme. Manikandan C; Kaushik A; Sen D Cancer Gene Ther; 2020 May; 27(5):270-279. PubMed ID: 31316136 [TBL] [Abstract][Full Text] [Related]
7. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics. Li R; Chen X; You Y; Wang X; Liu Y; Hu Q; Yan W Oncotarget; 2015 Oct; 6(31):30968-74. PubMed ID: 26427041 [TBL] [Abstract][Full Text] [Related]
8. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Verhaak RG; Hoadley KA; Purdom E; Wang V; Qi Y; Wilkerson MD; Miller CR; Ding L; Golub T; Mesirov JP; Alexe G; Lawrence M; O'Kelly M; Tamayo P; Weir BA; Gabriel S; Winckler W; Gupta S; Jakkula L; Feiler HS; Hodgson JG; James CD; Sarkaria JN; Brennan C; Kahn A; Spellman PT; Wilson RK; Speed TP; Gray JW; Meyerson M; Getz G; Perou CM; Hayes DN; Cancer Cell; 2010 Jan; 17(1):98-110. PubMed ID: 20129251 [TBL] [Abstract][Full Text] [Related]
9. Classification of glioblastoma multiforme in adults by molecular genetics. Benjamin R; Capparella J; Brown A Cancer J; 2003; 9(2):82-90. PubMed ID: 12784873 [TBL] [Abstract][Full Text] [Related]
10. Molecular and Genomic Alterations in Glioblastoma Multiforme. Crespo I; Vital AL; Gonzalez-Tablas M; Patino Mdel C; Otero A; Lopes MC; de Oliveira C; Domingues P; Orfao A; Tabernero MD Am J Pathol; 2015 Jul; 185(7):1820-33. PubMed ID: 25976245 [TBL] [Abstract][Full Text] [Related]
11. Glioblastoma: molecular analysis and clinical implications. Huse JT; Holland E; DeAngelis LM Annu Rev Med; 2013; 64():59-70. PubMed ID: 23043492 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments. Shen Y; Grisdale CJ; Islam SA; Bose P; Lever J; Zhao EY; Grinshtein N; Ma Y; Mungall AJ; Moore RA; Lun X; Senger DL; Robbins SM; Wang AY; MacIsaac JL; Kobor MS; Luchman HA; Weiss S; Chan JA; Blough MD; Kaplan DR; Cairncross JG; Marra MA; Jones SJM Proc Natl Acad Sci U S A; 2019 Sep; 116(38):19098-19108. PubMed ID: 31471491 [TBL] [Abstract][Full Text] [Related]
14. Comparison of glioblastoma (GBM) molecular classification methods. Lee E; Yong RL; Paddison P; Zhu J Semin Cancer Biol; 2018 Dec; 53():201-211. PubMed ID: 30031763 [TBL] [Abstract][Full Text] [Related]
15. Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies. Jarboe JS; Johnson KR; Choi Y; Lonser RR; Park JK Cancer Res; 2007 Sep; 67(17):7983-6. PubMed ID: 17804706 [TBL] [Abstract][Full Text] [Related]
16. Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. Gromeier M; Brown MC; Zhang G; Lin X; Chen Y; Wei Z; Beaubier N; Yan H; He Y; Desjardins A; Herndon JE; Varn FS; Verhaak RG; Zhao J; Bolognesi DP; Friedman AH; Friedman HS; McSherry F; Muscat AM; Lipp ES; Nair SK; Khasraw M; Peters KB; Randazzo D; Sampson JH; McLendon RE; Bigner DD; Ashley DM Nat Commun; 2021 Jan; 12(1):352. PubMed ID: 33441554 [TBL] [Abstract][Full Text] [Related]
17. Emerging insights into the molecular and cellular basis of glioblastoma. Dunn GP; Rinne ML; Wykosky J; Genovese G; Quayle SN; Dunn IF; Agarwalla PK; Chheda MG; Campos B; Wang A; Brennan C; Ligon KL; Furnari F; Cavenee WK; Depinho RA; Chin L; Hahn WC Genes Dev; 2012 Apr; 26(8):756-84. PubMed ID: 22508724 [TBL] [Abstract][Full Text] [Related]
18. Comprehensive genetic alteration profiling in primary and recurrent glioblastoma. Neilsen BK; Sleightholm R; McComb R; Ramkissoon SH; Ross JS; Corona RJ; Miller VA; Cooke M; Aizenberg MR J Neurooncol; 2019 Mar; 142(1):111-118. PubMed ID: 30535594 [TBL] [Abstract][Full Text] [Related]
19. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression. Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962 [TBL] [Abstract][Full Text] [Related]